AptarGroup Announces That Its Unidose Powder Nasal Spray System Is Being Utilized In ENA Respiratory's Phase II Clinical Study Of INNA 051

AptarGroup, Inc. (NYSE: ATR) announced that its Unidose (UDS) Powder Nasal Spray System is being used in ENA Respiratory's Phase II clinical study of INNA 051, a nasal spray aimed at protecting against symptomatic viral respiratory infections. This collaboration highlights the increasing importance of intranasal delivery technologies in developing new non-vaccine strategies for respiratory disease prevention.